Despite promising clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant opposition from pharmacy benefit managers. Such insurers are frequently erecting obstacles website to access, like steep cost requirements and approval processes that limit patient access. Industr